Results 21 to 30 of about 18,095,855 (237)

A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals

EJNMMI Radiopharmacy and Chemistry, 2021
Background As 225Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize quality control (QC) testing procedures.
James M. Kelly, Alejandro Amor-Coarasa, Elizabeth Sweeney, Justin J. Wilson, Patrick W. Causey, John W. Babich   +5 more
doaj   +1 more source

The design, synthesis, and evaluation of radiopharmaceuticals for actinium-225 [PDF]

, 2021
This thesis studies the design, synthesis, and optimization of radiopharmaceuticals for targeted alpha therapy applications with actinium-225 (225Ac). In Chapter 2, three novel radiopharmaceuticals - 2.1 (DOTA-CCZ-N-Me-α-CycMSH), 2.2 (Macropa-CCZ-N-Me- α-CycMSH), and 2.6 (Macropa-α-CycMSH) for malignant melanoma therapy were labeled with 225Ac and ...
Brown, Victoria
openaire   +2 more sources

Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer: in vitro evaluation, dosimetric assessment and detector calibration

EJNMMI Radiopharmacy and Chemistry, 2023
Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy which may benefit from radioimmunotherapy. Previously, [177Lu]Lu-DOTA-C595 has been developed as a beta-emitting radioimmunoconjugate to target cancer-specific mucin 1 ...
Ashleigh Hull, William Hsieh, Artem Borysenko, William Tieu, Dylan Bartholomeusz, Eva Bezak   +5 more
doaj   +1 more source

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

OncoImmunology, 2021
Multiple myeloma (MM) is a hematological malignancy characterized by the presence of clonal plasma cells in the bone marrow niche. Despite significant therapeutic advances, MM remains incurable for the majority of patients. Targeted radionuclide therapy (
Kim De Veirman, Janik Puttemans, Ahmet Krasniqi, Thomas Ertveldt, Heleen Hanssens, Ema Romao, Dirk Hose, Cleo Goyvaert, Philip Vlummens, Serge Muyldermans, Karine Breckpot, Frank Bruchertseifer, Alfred Morgenstern, Matthias D’Huyvetter, Nick Devoogdt   +14 more
doaj   +1 more source

Ac-EAZY! Towards GMP-Compliant Module Syntheses of ²²⁵Ac-Labeled Peptides for Clinical Application

Pharmaceuticals, 2021
The application of 225Ac (half-life T1/2 = 9.92 d) dramatically reduces the activity used for peptide receptor radionuclide therapy by a factor of 1000 in comparison to 90Y, 177Lu or 188Re while maintaining the therapeutic outcome.
Marc Pretze, Falk Kunkel, Roswitha Runge, Robert Freudenberg, Anja Braune, Holger Hartmann, Uwe Schwarz, Claudia Brogsitter, Jörg Kotzerke   +8 more
doaj   +1 more source

²²⁵Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic

Pharmaceutics, 2023
The widespread use of peptide receptor radionuclide therapy (PRRT) represents a major therapeutic breakthrough in nuclear medicine, particularly since the introduction of 177Lu-radiolabeled somatostatin analogs. These radiopharmaceuticals have especially
Léa Rubira, Emmanuel Deshayes, Lore Santoro, Pierre Olivier Kotzki, Cyril Fersing   +4 more
doaj   +1 more source

Actinium-225 in Targeted Alpha-Particle Therapeutic Applications [PDF]

Current Radiopharmaceuticalse, 2011
Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous ...
David A, Scheinberg, Michael R, McDevitt
openaire   +2 more sources

Advances in ¹⁷⁷Lu-PSMA and ²²⁵Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer

Pharmaceutics, 2022
For patients with metastatic castration-resistant prostate cancer (mCRPC), the survival benefit of classic treatment options with chemotherapy and drugs targeting androgen signaling is limited.
Sui Wai Ling, Erik de Blois, Eline Hooijman, Astrid van der Veldt, Tessa Brabander   +4 more
doaj   +1 more source

Data publication: One chelator for imaging and therapy with lutetium-177 and actinium-225

, 2023
Bei diesem Datensatz handelt es sich um analytische Charakterisierungen (ESI-MS, HR-MS, MALDI-TOF-MS) und Radiomarkierungsuntersuchungen zum nonadentaten Bispidin-Chelator bzw.
Bachmann, Michael, Wadepohl, Hubert, Pietzsch, Jens, Zarschler, Kristof, Cieslik, Patrick, Brandt, Florian, Anger, Karl, Ullrich, Martin, Kopka, Klaus, Stephan, Holger, Comba, Peter, Kubeil, Manja   +11 more
core   +1 more source

Development of a multi faceted platform containing a tetrazine, fluorophore and chelator: synthesis, characterization, radiolabeling, and immuno-SPECT imaging

EJNMMI Radiopharmacy and Chemistry, 2022
Background Combining optical (fluorescence) imaging with nuclear imaging has the potential to offer a powerful tool in personal health care, where nuclear imaging offers in vivo functional whole-body visualization, and the fluorescence modality may be ...
Anthony W. McDonagh, Brooke L. McNeil, Julie Rousseau, Ryan J. Roberts, Helen Merkens, Hua Yang, François Bénard, Caterina F. Ramogida   +7 more
doaj   +1 more source